Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

Published Date: 09 Dec 2024

Two-thirds of phase II patients had a complete response at 12 weeks of treatment

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

2.

Fitness levels for the heart and lungs are linked to a lower mortality from cancer in men.

3.

"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.

4.

Multiple Myeloma Patients Have Unequal Access to Treatment

5.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot